Dhampur Bio

Why is Dhampur Bio Organics Ltd falling/rising?

As of 03-Sep, Dhampur Bio Organics Ltd's stock price is at 130.00, reflecting a 1.33% increase. The stock has risen 5.07% over the past week and 26.85% over the past month, significantly outperforming the Sensex, despite a decline in investor participation.

As of 03-Sep, Dhampur Bio Organics Ltd is experiencing a rise in its stock price, currently at 130.00, which reflects a change of 1.7 (1.33%) upwards. This increase can be attributed to several factors. Over the past week, the stock has risen by 5.07%, significantly outperforming the Sensex, which has declined by 1.01% during the same period. Additionally, the stock has shown impressive gains over the past month, with a rise of 26.85%, while the Sensex has fallen by 3.16%. Year-to-date, the stock has increased by 64.20%, contrasting with the Sensex's decline of 10.64%.<BR><BR>Moreover, Dhampur Bio has been on a consecutive gain streak for the last five days, accumulating a total return of 3.94% in that timeframe. The stock is also trading above its moving averages across various periods, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a strong upward trend.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 60.73% against the 5-day average. Despite this, the stock remains liquid enough for trading, suggesting that while participation may be falling, the stock's price is still rising due to its strong performance relative to the market and its moving averages.

Which are the latest news on Dhampur Bio?

Who are in the management team of Dhampur Bio?

The management team of Dhampur Bio includes V K Goel (Executive Chairman), A K Gupta (Vice Chairman), Gautam Goel (Managing Director), Sandeep Kumar Sharma (Whole-time Director), and several independent directors, along with Ashu Rawat as Company Secretary & Compliance Officer.

The management team of Dhampur Bio includes the following individuals:<BR><BR>1. V K Goel - Executive Chairman<BR>2. A K Gupta - Vice Chairman<BR>3. Gautam Goel - Managing Director<BR>4. Sandeep Kumar Sharma - Whole-time Director<BR>5. Bindu Vashist Goel - Director<BR>6. Ruchika Mehra Kothari - Independent Director<BR>7. Vishal Saluja - Independent Director<BR>8. Samir Thukral - Independent Director<BR>9. Kishor Shah - Independent Director<BR>10. Ashu Rawat - Company Secretary & Compliance Officer<BR><BR>If you need more information about their roles or the company, feel free to ask!

What does Dhampur Bio do?

Dhampur Bio Organics Ltd is a micro-cap company in the sugar industry, incorporated in 2020 and converted to a public company in 2021, with net sales of 533 Cr and a net profit of 37 Cr as of June 2026. Key metrics include a P/E of 30.00, a dividend yield of 1.19%, and a market cap of INR 842 Cr.

Overview:<BR>Dhampur Bio Organics Ltd operates in the sugar industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 2020 under the name "RMSD Enterprises Private Limited" and later converted to a public limited company named "Dhampur Bio Organics Limited" in 2021. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 533 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 37 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 842 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 30.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 1.19% <BR>Debt-Equity: 1.00 <BR>Return on Equity: 2.74% <BR>Price to Book: 0.81 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Dhampur Bio?

Dhampur Bio's peers include Avadh Sugar, Uttam Sug.Mills, Dhampur Sugar, Dwarikesh Sugar, Zuari Industries, Magadh Sugar, Ugar Sugar Works, Mawana Sugars, DCM Shriram Inds, and M.V.K. Agro. Avadh Sugar leads with a 1-year return of 108.16%, while Dhampur Bio has a return of 50.33%, and Zuari Industries has the lowest return at -12.65%.

Peers: The peers of Dhampur Bio are Avadh Sugar, Uttam Sug.Mills, Dhampur Sugar, Dwarikesh Sugar, Zuari Industries, Magadh Sugar, Ugar Sugar Works, Mawana Sugars, DCM Shriram Inds, and M.V.K. Agro.<BR><BR>Quality Snapshot: Excellent management risk is observed at M.V.K. Agro, while Average management risk is found at Avadh Sugar, Uttam Sug.Mills, Dhampur Sugar, Dwarikesh Sugar, Magadh Sugar, Ugar Sugar Works, Mawana Sugars, DCM Shriram Inds, and Dhampur Bio. Below Average management risk is noted at Zuari Industries. Growth is Excellent at M.V.K. Agro, while Average growth is seen at Dwarikesh Sugar, Zuari Industries, and the rest have Below Average growth. Capital Structure ratings show Average at Dwarikesh Sugar and DCM Shriram Inds, while the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Avadh Sugar at 108.16%, while Zuari Industries has the lowest at -12.65%. Dhampur Bio's 1-year return of 50.33% is higher than Zuari Industries but lower than Avadh Sugar. Additionally, Zuari Industries is the only peer with a negative six-month return.

How big is Dhampur Bio?

As of 31st August, Dhampur Bio Organics Ltd has a market capitalization of 842.00 Cr, with recent net sales of 2036.48 Cr and a net profit of 83.97 Cr. The latest balance sheet shows shareholder's funds of 1,026.64 Cr and total assets of 2,322.13 Cr.

As of 31st August, Dhampur Bio Organics Ltd has a market capitalization of 842.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 2036.48 Cr and a Net Profit of 83.97 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, showing Shareholder's Funds of 1,026.64 Cr and Total Assets of 2,322.13 Cr.

Should I buy, sell or hold Dhampur Bio Organics Ltd?

Are Dhampur Bio Organics Ltd latest results good or bad?

Dhampur Bio Organics Ltd's latest results are unfavorable, showing a net loss of ₹13.75 crores for Q1 FY27, a significant decline from a profit in the previous quarter, alongside sharply reduced operating margins. Investors are advised to consider a "SELL" rating due to ongoing operational inefficiencies and low return on equity.

The latest results for Dhampur Bio Organics Ltd. indicate a challenging quarter. While the company experienced a sequential increase in net sales of 15.96%, reaching ₹532.89 crores, this growth did not translate into profitability. The operating margins, excluding other income, fell sharply to 1.68% from 17.40% in the previous quarter, highlighting significant margin compression.<BR><BR>The company reported a net loss of ₹13.75 crores for Q1 FY27, which is a substantial decline from a profit of ₹38.41 crores in the previous quarter. This represents a 295.50% decrease in net profit quarter-over-quarter. Year-on-year, the situation is also concerning, as the net profit swung from a loss of ₹22 crores in Q1 FY26 to the current loss.<BR><BR>The results reflect ongoing operational inefficiencies and high interest costs, which have severely impacted profitability. Additionally, the company's return on equity stands at a low 2.89%, indicating poor utilization of shareholder capital. Given these factors, the overall assessment of the latest results leans towards being unfavorable, with a "SELL" rating recommended for investors.

When is the next results date for Dhampur Bio Organics Ltd?

The next results date for Dhampur Bio Organics Ltd is 14 July 2026.

The next results date for Dhampur Bio Organics Ltd is scheduled for 14 July 2026.

Is Dhampur Bio technically bullish or bearish?

As of December 2, 2025, Dhampur Bio's technical trend is neutral with mixed indicators, showing a mildly bearish weekly and monthly MACD, mildly bullish daily moving averages, and a lack of strong momentum overall.

As of 2 December 2025, the technical trend for Dhampur Bio has changed from mildly bearish to sideways. The current stance is neutral, with mixed indicators influencing the outlook. The weekly MACD remains bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The Bollinger Bands also reflect a mildly bearish sentiment on both weekly and monthly time frames. However, the daily moving averages show a mildly bullish signal, suggesting some short-term strength. The Dow Theory indicates a mildly bullish stance on the weekly chart, but no trend is present on the monthly chart. Overall, the technical indicators present a conflicting picture, leading to a neutral stance with no strong bullish or bearish momentum.

How has been the historical performance of Dhampur Bio?

Dhampur Bio's historical performance shows a decline in net sales, operating profit, and profit after tax over the past four years, with significant drops from March 2023 to March 2025, despite an increase in total assets and liabilities. Cash flow from operating activities turned negative in March 2024, indicating a downward trend in profitability.

Answer:<BR>The historical performance of Dhampur Bio shows fluctuations in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Dhampur Bio's net sales for the year ending March 2025 were reported at 1,861.54 crore, slightly down from 1,864.44 crore in March 2024 and significantly lower than 2,407.53 crore in March 2023. The total operating income mirrored this trend, remaining almost flat from the previous year but showing a decline from the prior two years. The total expenditure, excluding depreciation, was 1,726.74 crore in March 2025, a minor decrease from 1,728.01 crore in March 2024, yet lower than 2,202.81 crore in March 2023. Operating profit (PBDIT) for March 2025 was 138.46 crore, down from 160.30 crore in March 2024 and 216.14 crore in March 2023. Profit before tax also saw a decline to 15.71 crore in March 2025 from 65.49 crore in March 2024 and 134.77 crore in March 2023. Consequently, profit after tax dropped to 14.69 crore in March 2025 from 46.49 crore in March 2024 and 111.10 crore in March 2023. The company's total assets increased to 2,397.53 crore in March 2025 from 2,312.81 crore in March 2024, while total liabilities also rose to 2,397.53 crore from 2,312.81 crore in the same period. Cash flow from operating activities turned negative at -101 crore in March 2024, contrasting with a positive cash flow of 368 crore in March 2023. Overall, the financial performance of Dhampur Bio indicates a downward trend in profitability and sales over the last few years, despite an increase in total assets and liabilities.

Is Dhampur Bio overvalued or undervalued?

As of October 10, 2025, Dhampur Bio is considered very attractive and undervalued, with a PE ratio of -95.86, a low price-to-book value of 0.54, and an EV to EBITDA ratio of 16.15, especially when compared to peers like EID Parry and Balrampur Chini, despite its year-to-date stock performance lagging at -28.53% against the Sensex's 5.58%.

As of 10 October 2025, the valuation grade for Dhampur Bio has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, particularly when analyzing its key ratios. The PE ratio stands at -95.86, while the price-to-book value is a low 0.54, suggesting that the stock is trading well below its book value. Additionally, the EV to EBITDA ratio is 16.15, which, while higher than some peers, still reflects a favorable valuation in the context of the overall market.<BR><BR>In comparison to its peers, Dhampur Bio's valuation metrics stand out. EID Parry, categorized as very expensive, has a PE ratio of 23.46, while Balrampur Chini, rated fair, shows a PE of 23.07. This stark contrast highlights Dhampur Bio's undervaluation relative to its competitors. Furthermore, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -28.53% compared to the Sensex's 5.58%. This underperformance reinforces the notion that the stock may be undervalued, presenting a potential opportunity for investors.

Who are the top shareholders of the Dhampur Bio?

The top shareholders of Dhampur Bio include Sonitron Limited with 17.28%, individual investor Anil Kumar Goel at 9.04%, and individual investors collectively holding 40.43%. Additionally, 12 foreign institutional investors hold 0.54%, while mutual funds have no significant holdings.

The top shareholders of Dhampur Bio include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sonitron Limited, which owns 17.28% of the company. In terms of public shareholders, Anil Kumar Goel is the largest individual investor, holding 9.04%. Additionally, individual investors collectively hold 40.43% of the shares. There are also 12 foreign institutional investors (FIIs) with a combined holding of 0.54%, and three mutual fund schemes that hold 0.0%.

Has Dhampur Bio declared dividend?

Yes, Dhampur Bio Organics Ltd has declared a 25% dividend, amounting to ₹2.5 per share, with an ex-date of June 28, 2024. However, the company has experienced significant price declines, resulting in total returns of -38.81% over the last 6 months and -34.19% over the past year.

Dhampur Bio Organics Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: Jun-28-2024<BR><BR>Dividend Yield: 3.29%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -38.81%, the dividend return was 0%, resulting in a total return of -38.81%.<BR><BR>Over the past year, the price return was -36.03%, with a dividend return of 1.84%, leading to a total return of -34.19%.<BR><BR>For the 2-year period, the price return was -50.95%, the dividend return was 3.35%, culminating in a total return of -47.6%.<BR><BR>In the 3-year timeframe, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 4 years, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Dhampur Bio has declared a dividend, the total returns over various periods indicate significant declines in price, particularly over the last 6 months and 1 year, highlighting a challenging performance despite the dividend yield.